牛牛AI助手已提取核心信息
On December 31, 2023, an amendment to Schedule 13G was filed with the SEC by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker, collectively referred to as the Reporting Persons, regarding their ownership in HOOKIPA Pharma Inc. The amendment reports that the Reporting Persons collectively own 8,148,985 shares of HOOKIPA Pharma, representing 9.99% of the company's outstanding common stock. This ownership includes shares issuable upon conversion of Series A-2 Preferred Stock, subject to certain ownership limitations. The Reporting Persons have complete discretion and authority over the investment and voting power of these securities due to management agreements with the funds holding the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of HOOKIPA Pharma.
On December 31, 2023, an amendment to Schedule 13G was filed with the SEC by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and individuals Julian C. Baker and Felix J. Baker, collectively referred to as the Reporting Persons, regarding their ownership in HOOKIPA Pharma Inc. The amendment reports that the Reporting Persons collectively own 8,148,985 shares of HOOKIPA Pharma, representing 9.99% of the company's outstanding common stock. This ownership includes shares issuable upon conversion of Series A-2 Preferred Stock, subject to certain ownership limitations. The Reporting Persons have complete discretion and authority over the investment and voting power of these securities due to management agreements with the funds holding the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of HOOKIPA Pharma.
2023年12月31日，贝克兄弟顾问有限责任公司、贝克兄弟顾问（GP）有限责任公司以及个人朱利安·贝克和费利克斯·贝克（统称为申报人）就其在HOOKIPA Pharma Inc.的所有权向美国证券交易委员会提交了附表13G的修正案。该修正案报告称，申报人共拥有HOOKIPA Pharma的8,148,985股股份，占该公司已发行普通股的9.99％。该所有权包括转换A-2系列优先股后可发行的股票，但须遵守某些所有权限制。根据与持有证券的基金签订的管理协议，申报人对这些证券的投资和投票权拥有完全的自由裁量权和权力。文件显示，这些股份是在正常业务过程中收购的，不是为了改变或影响HOOKIPA Pharma的控制权。
2023年12月31日，贝克兄弟顾问有限责任公司、贝克兄弟顾问（GP）有限责任公司以及个人朱利安·贝克和费利克斯·贝克（统称为申报人）就其在HOOKIPA Pharma Inc.的所有权向美国证券交易委员会提交了附表13G的修正案。该修正案报告称，申报人共拥有HOOKIPA Pharma的8,148,985股股份，占该公司已发行普通股的9.99％。该所有权包括转换A-2系列优先股后可发行的股票，但须遵守某些所有权限制。根据与持有证券的基金签订的管理协议，申报人对这些证券的投资和投票权拥有完全的自由裁量权和权力。文件显示，这些股份是在正常业务过程中收购的，不是为了改变或影响HOOKIPA Pharma的控制权。
有用
没用